Hypertension Care » read post

Gilead Announces Presentation of Long-Term Data for Ambrisentan, a


Gilead Announces Presentation of Long-Term Data for Ambrisentan, a
GILD) today announced results of two long-term studies Potential Treatment for Patients W ith Pulmonary Arterial Hypertension progressive, life-threatening disease for which new
Source: www.businesswire.com

The new clinical trials on pharmacological treatment in pulmonary
congenital systemic-to-pulmonary shunts 7, portal hypertension 8 and human The new compounds that were tested in these studies are the thromboxane inhibitor terbogrel 27, the
Source: erj.ersjournals.com

Narrative Review: The Enigma of Pulmonary Arterial Hypertension: New
The Enigma of Pulmonary Arterial Hypertension: New Insightsfrom Genetic Studies JohnH. These illnesses include connective tissue diseases, portal hypertension, diet
Source: www.annals.org

Caremark
The FDA approved its use for pulmonary hypertension in 2004. Studies have shown that it can Pulmonary Hypertension: New Perspectives. Medscape, www.medscape.com
Source: www.caremark.com

Effects of chronic portal hypertension on agonist-induced actin
of chronic portal hypertension on with our previous studies showing that PKA inhibition restored the impaired vasoconstrictor function in portal hypertension smooth muscle: a new
Source: ajpheart.physiology.org

Complications of Cirrhosis and Portal Hypertension-Variceal Bleeding
portal hypertension new therapies, were matched by some very exciting developments in the field of portal hypertension studies (N = 595) assessing the role of HVPG guidance in the pharmacologic management of portal hypertension
Source: www.medscape.com

Tags: , , , ,